Capitalizing on the ‘Ozempic Face’ Phenomenon: Galderma Seizes Opportunity to Boost Demand for Facial Fillers

The Swiss pharmaceutical company, Galderma, is seizing the opportunity presented by the “Ozempic face” phenomenon. The CEO believes that the increasing popularity of weight-loss drugs like Ozempic could lead to an increase in demand for their facial filler products. This is because Ozempic can cause a sunken-in look in some patients’ faces, which fillers can help to counteract.

Galderma has several products on offer that are designed to restore the gaunt look associated with “Ozempic face.” One such product is Sculptra, which has been shown to be effective in restoring volume and contour to the face. The company has also started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.

Some dermatologists have noted that “Ozempic face” has become increasingly common in their practices due to the widespread use of weight-loss medications. The term refers to the sunken and aged appearance that can result from rapid weight loss. Galderma, which went public last month on the SIX Swiss Exchange, reported a 12.4% increase in sales year-over-year in the first quarter of the year. The company also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on the trend of weight-loss drugs like Ozempic.

In conclusion, Galderma is taking advantage of an opportunity presented by “Ozempic face.” The CEO believes that weight-loss drugs like Ozempic could lead to an increase in demand for their facial filler products as they can help counteract the sunken-in look caused by rapid weight loss. With a growing number of patients using GLP-1 treatments for weight loss and its own range of facial fillers products on offer, Galderma is well positioned to capitalize on this trend.